INTENSITY THERAPEUTICS, INC.

INTS Nasdaq CIK: 0001567264

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 1 ENTERPRISE DRIVE, SUITE 430, SHELTON, CT, 06484
Mailing Address 1 ENTERPRISE DRIVE, SUITE 430, SHELTON, CT, 06484
Phone 203-221-7381
Fiscal Year End 1231
EIN 461488089

Financial Overview

FY2024

$17.30M
Total Assets
$4.13M
Total Liabilities
$2.92M
Stockholders' Equity
$8.56M
Cash & Equivalents
$-1.17
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 13, 2026 View on SEC
4 Insider stock transaction report January 5, 2026 View on SEC
4 Insider stock transaction report January 5, 2026 View on SEC
8-K Current report of material events December 5, 2025 View on SEC
8-K Current report of material events December 4, 2025 View on SEC
424B5 Prospectus supplement December 4, 2025 View on SEC
8-K Current report of material events November 6, 2025 View on SEC
10-Q Quarterly financial report November 6, 2025 View on SEC
424B5 Prospectus supplement November 3, 2025 View on SEC
8-K Current report of material events October 31, 2025 View on SEC

Material Events

8-K Financial Distress February 13, 2026
High Impact
  • Regaining Nasdaq compliance to avoid delisting.
  • Improving marketability and attracting institutional investors.
View Analysis
8-K Financial Distress December 5, 2025
High Impact
  • INTENSITY THERAPEUTICS, INC. received an extension from Nasdaq to regain compliance with the minimum bid price requirement.
  • The company's stock price has been trading below $1.00 per share, violating Nasdaq's listing rules.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.